FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

|--|

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* O'Keeffe Charles B				<u>C</u> A	2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. [CPRX]							(Che	5. Relationship of Repor (Check all applicable) X Director			10% Ow	ner		
(Last)	,	rst) (CIRCLE, SUITE	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/27/2023									Officer (give title below)		Other (s below)	pecify	
(Street)			- 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person								
GABLES	S FI	<u>.</u>	33134												Persor		e thar	n One Repor	ting
(City) (State) (Zip)				Rı	Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Code	Transaction Disposed Of (D) (Ir Code (Instr. 5)					5. Amount of Securities Beneficially Owned tollowing		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) (D)	or	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
Common Stock, par value \$0.001 per share 12/27.			7/202	3			М		1,33	3 A		(1) 621,724		,724		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C				Fransaction of Code (Instr. Derivative		Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa		expiration Pate	Title	or Nu of	ımber					
Restricted Stock Units	(1)	12/27/2023			М			1,333	(2)		(3)	Common Stock	1,	,333	\$0	292,93	1	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- 2. Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025.
- 3. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 27, 2023.

12/29/2023 /s/ Charles B. O'Keeffe

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.